Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: A comparative review

Drug Safety

Volumn 25, Issue 11, 2002, Pages 781-790

  Kherani, Raheem B ^a   Papaioannou, Alexandra ^a   Adachi, Jonathan D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RISEDRONIC ACID;

ABDOMINAL PAIN; BONE BIOPSY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; DYSPEPSIA; EVALUATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; META ANALYSIS; METHODOLOGY; NAUSEA; OSTEOMALACIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKELETON MALFORMATION; VERTEBRA FRACTURE;

EID: 0036398265     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225110-00003     Document Type: Review

References (38)

1. Wiktorowicz ME, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12: 271-8
2. Woo T, Adachi JD. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol 2001; 15: 469-81
3. DIDROCAL® Monograph. In: Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties. Toronto (ON): Webcom Limited, 2002
4. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71
5. Cranney A, Guyatt G, Krolicki N, et al., on behalf of the Osteoporosis Research Advisory Group. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12: 140-51
6. Cranney A, Wells G, Willan A, et al. Meta-analyses of osteoporosis therapies. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16
7. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of osteoporosis therapies. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-23
8. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
9. Black DM, Cummings SR, Karpf DB, et al., on behalf of the Fracture Intervention Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
10. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
11. Pols HAP, Felsenberg D, Hanley D, et al. Multinational, placebo controlled, randomized trial of effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 8: 461-8
12. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-52
13. Reginster J, Minne H, Sorensen O, et al., on behalf of the Vertebral Efficacy with Risedronate Therapy Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91
14. McClung MR, Geusens P, Miller PD, et al., for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women, than low bone mineral density. N Engl J Med 2001; 344: 333-40
15. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997; 103: 468-76
16. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol 1999; 18: 349-50
17. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97: 58-64
18. FOSAMAX® Monograph. In: Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties. Toronto (ON): Webcom Limited, 2002
19. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21
20. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107-10
21. Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162: 936-42
22. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160: 517-25
23. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12
24. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109-15
25. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997; 82: 265-74
26. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-80
27. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000; 22: 1433-42
28. ACTONEL® Monograph. In: Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties. Toronto (ON): Webcom Limited, 2002
29. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1890-7
30. Cortet B, Bera-Louville A, Gauthier P, et al. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis: effect of adding hormone replacement therapy. Joint Bone Spine 2001; 68: 410-5
31. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 3112-7
32. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001; 13: 347-54
33. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69: 281-6
34. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-8
35. Saag KG, Emkey R, Schnitzer TJ, et al., for the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9
36. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006-13
37. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-18
38. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000; 29: 228-51